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Abstract
Themechanisms underlying preferential atrophy of the striatum in Huntington’s disease (HD) are unknown. One hypothesis is
that a set of gene products preferentially expressed in the striatum could determine the particular vulnerability of this brain
region tomutant huntingtin (mHtt). Here, we studied the striatal protein μ-crystallin (Crym). Crym is theNADPH-dependent p38
cytosolic T3-binding protein (p38CTBP), a key regulator of thyroid hormone (TH) T3 (3,5,3′-triiodo--thyronine) transportation.
It has been also recently identiﬁed as the enzyme that reduces the sulfur-containing cyclic ketimines, which are potential
neurotransmitters. Here, we conﬁrm the preferential expression of the Crymprotein in the rodent andmacaque striatum. Crym
expressionwas found to be higher in themacaque caudate than in the putamen. Expression of Crymwas reduced in the BACHD
and Knock-in 140CAG mouse models of HD before onset of striatal atrophy. We show that overexpression of Crym in striatal
medium-size spiny neurons using a lentiviral-based strategy in mice is neuroprotective against the neurotoxicity of an
N-terminal fragment of mHtt in vivo. Thus, reduction of Crym expression in HD could render striatal neurons more susceptible
tomHtt suggesting that Crymmay be a key determinant of the vulnerability of the striatum. In addition ourwork points to Crym
as a potential molecular link between striatal degeneration and the THs deregulation reported in HD patients.
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The protein μ-crystallin (Crym) has been discovered as a highly
enriched lens component in Marsupials (1). Crym was identiﬁed
as the NADPH-dependent p38 cytosolic T3-binding protein
[p38CTBP, also known as THBP for thyroid hormone (TH)-binding
protein], which is likely a key regulator of the TH T3 (3,5,3′-triio-
do--thyronine) transportation in cytoplasm and nucleus, a
mechanism throughwhich it is involved in regulating TH-related
gene expression (2). Indeed, in the nucleus T3 binds to thyroid
hormone receptor-containing dimers, which bind to genomic
thyroid responsive elements to regulate gene transcription (3).
Although Crym expression in the brain is high (4), its neurobio-
logical function is unknown. Several observations indirectly sug-
gest that Crym could be a crucial determinant of neuronal cell
death/survival. Crym has been reported to be an actor of macular
degeneration in non-human primates (5). Mutations in the Crym
gene lead to non-syndromic deafness, possibly by the incapacity
of the resulting mutants to be involved in the potassium ion re-
cycling system with Na, K-ATPase (6,7). Recently, mutations in
CRYM have been tentatively related to amyotrophic lateral scler-
osis (ALS) (8). Given that many species-speciﬁc crystallins with
NADPH-binding properties are protective against oxidation in
the lens (2), upregulated Crym in microglia cells in late stages of
ALS may have a protective effect against neurodegeneration as
do other NADPH requiring enzymes such as thioredoxin (9).
Further supporting the view that Crym plays a central role in
the central nervous system, Hallen and collaborators recently
demonstrated using puriﬁcation and MS/MS identiﬁcation that
the enzyme ketimine reductase (E.C. 1.5.1.25) is actually Crym
(10). Thus, Crym catalyzes the reduction of sulfur-containing
substrates known as cyclic ketimines that derive from sulfur-
containing amino acids and may play a potential role as neuro-
transmitters (10). Interestingly, the enzymatic activity of ketimine
reductase is regulated by T3 levels. Thus, Crym may play a key
role at the interface between metabolism, neurotransmission
and cell survival.
We recently focused our interest on Crym because of its pref-
erential expression in the striatum and its possible involvement
in the pathogenesis of Huntington’s disease (HD) (11,12). HD is an
autosomal dominant hereditary neurodegenerative disorder
characterized by a preferential atrophy of the striatumassociated
with cognitive, psychiatric and motor symptoms (13). HD is
caused by an abnormal CAG repeat expansion in the huntingtin
(htt) gene (14).Mutant huntingtin (mHtt) is neurotoxic to neurons,
especially toward neurons of the striatum, through both a gain of
function and a loss of function (15). mHtt produces anomalies in
energy production and oxidative stress (16), Ca2+ deregulation
and excitotoxicity (17), abnormal trophic factor expression, traf-
ﬁcking and release (15), alterations of cytoskeleton-mediated
transport machinery (18) and defects in signaling pathways in-
volved in cell survival (19). However, none of these mechanisms
can explain per se the preferential vulnerability of the striatum in
HD. One hypothesis is that a set of factors, selectively expressed
in the striatum may confer to striatal GABAergic projection neu-
rons their particular susceptibility in HD (for a review 20). For ex-
ample, the presence of the dopamine subtype 2 receptors (21–23),
the small GTPase Rhes through its E3-ubiquitin ligase activity (24)
and the RGS2 protein (25) in striatal neurons have been shown to
increase their susceptibility to mHtt in HD. On the contrary, the
reduced expression of several proteins with preferential expres-
sion in the striatum, and shown to possess neuroprotective prop-
erties may also increase the vulnerability of striatal neurons,
such as adenosine type 2 receptors (A2A-R) (26), cannabinoid
type 1 receptors (CB1-R) (27,28) andmitogen- and stress-activated
kinase-1 (MSK-1) (29,30).
We previously found that the level of mRNA expression of
Crym, which we identiﬁed for its enriched expression in the stri-
atum and accumbens, is signiﬁcantly reduced by 50% in the stri-
atum of R6/2 mice (11), a widely used transgenic model of HD.
Retrospective analysis of gene array datasets of the striatum of
HD patients and transgenic mouse models of HD conﬁrms that
Crym mRNA levels are reduced in HD (31,32). Thus, it is possible
that Crym may be involved in striatal vulnerability through two
possible ways: reduction of Crym expression could be a causal
event leading to death/dysfunction, pointing to Crym as a neuro-
protective/pro-survival protein. On the opposite, decreased ex-
pression of Crym in HD could be a regulatory/compensatory
mechanism, if the presence Crym (like Rhes for instance) contri-
butes to the vulnerability of striatal neurons.
The objective of the present study was to investigate whether
the levels of Crym expression in the mouse striatum could
change the toxicity of mHtt. We ﬁrst characterized the enrich-
ment of the protein Crym in the striatum inmouse, rat and cyno-
molgus monkey. Secondly, we examined the expression of Crym
mRNA and protein in genetic mouse models of HD in absence of
major striatal degeneration (BACHD transgenic mice and Knock-
in 140CAGmice). Finally,we used a lentiviral vector (LV) approach
(33) to overexpress recombinant Crym in striatal neurons and dir-
ectly determine whether the protein could modulate mHtt tox-
icity in vivo in mice.
Results
Crym is expressed preferentially in the striatum
and localized in the cytosol
While the expression of CrymmRNAwas shown to be highly en-
riched in the striatum and accumbens, the expression of the pro-
tein had been rarely assessed. For this reason, a chicken IgY
antibody was raised against Crym (anti-Crym). Western blot ana-
lysis of striatal and cortical extracts (total protein extracts) pre-
pared from adult rats, mice and a male adult non-human
primate (macaca fascicularis) showed that endogenous Crym,
appearing at an apparent molecular weight of ∼37 kDa was pref-
erentially expressed in the striatum (caudate/putamen) when
compared with cerebral cortex (Fig. 1A and B). In a non-human
primate, Crym expression was markedly higher in the caudate
than in the putamen (Fig. 1B and C).
Experiments using differential centrifugation of rat brain
samples followed by western blot analysis showed that Crym
was mainly localized in the cytosol with low expression in the
membrane fraction (Fig. 2). Similar results were obtained in
mouse cerebral cortex and striatum (not shown). Thus, these re-
sults conﬁrmed that Crym is a cytosolic protein preferentially ex-
pressed in the striatum when compared with cerebral cortex in
the adult brain. In the primate striatum, levels of the protein
are higher in caudate than in putamen, consistentwithmRNA le-
vels described for themacaque and human brain (see Allen Brain
Atlas).
Recombinant Crym protein is localized in the cytoplasm
and nucleus
Little is known about the expression of Crym in cells, especially
neurons. The cDNA for mouse Crym was cloned and a sequence
encoding an hemagglutinin (HA) tagwas added to its 3′ end. After
transfection of HEK293T cell using this construct, expression of
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the recombinant protein was assessed by western blot using an
anti-HA antibody. A single band migrating at ∼37 kDa was de-
tected,which is consistentwith the theoretical apparentmolecu-
lar weight of full-length Crym andwith the signal obtained using
the anti-Crym antibody (Fig. 3A). Confocalmicroscopy analysis of
HEK cells transfected with the Crym-HA construct using im-
munoﬂuorescence detection of the HA tag indicated that Crym
was located ubiquitously throughout the cell, including the nu-
cleus and cell processes (Fig. 3B). Transfection of primary cul-
tures of striatal neurons was also performed with a construct
expressing Crym fused to the green ﬂuorescent protein (GFP-
Crym). Confocal microscopy analysis of the transfected neurons
also indicated that GFP-Crym was located ubiquitously through-
out the soma, the distal portions of neurites and within the
nucleus (Fig. 3C).
Finally, to study the subcellular localization of recombinant
Crym in vivo, we generated an LV encoding Crym-HA (LV-Crym-
HA) driven by the mouse PGK promoter. The LVs that we use al-
most exclusively transduce neurons in vivo and in vitro (21,34,35).
Adult C57Bl/6 mice received intrastriatal injection of the LV-
Crym-HA and 6 weeks later, brains were processed for histo-
chemical evaluation. Immunohistochemical detection of the
HA tag showed that the recombinant protein ﬁlled the entire
soma and dendrites of neurons (Fig. 4). The nucleus was also
stained. Confocal analysis of the striatum in mice injected with
LV-Crym-HA conﬁrmed that indeed, striatal neurons displayed
high levels of Crym in the cytoplasm and dendrites branches
and spines as well as in the nucleus (not shown).
Crym expression is reduced in HD models
Crym mRNA expression has been found to be reduced in HD
models and patients (11,31,32). Here, we studied its expression
in two additional genetic mouse models of HD. Analysis with
qRT-polymerase chain reaction (PCR) showed that Crym mRNA
levels were signiﬁcantly reduced by 43% in the striatum of
heterozygous BACHD mice at 6 months of age (mean mRNA
expression ± S.E.M., wild-type littermates (n = 5), 5.96 ± 0.186;
BACHD (n = 6), 3.38 ± 0.41; P < 0.0005, unpaired Student’s t-test;
not shown). Similarly, signiﬁcant decrease in CrymmRNA levels
was found in homozygous and to a lesser extent in heterozygous
KI140CAG mice (13 months of age) when compared with wild-
type mice (mean mRNA expression ± S.E.M., wild-type litter-
mates (n = 8), 0.090 ± 0.009; heterozygous KI140CAG mice (n = 8),
0.080 ± 0.005; P < 0.05; homozygous KI140CAG mice (n = 8), 0.05 ±
0.005; P < 0.01. One-way ANOVA: P < 0.0001; F = 9.948; post hoc
Bonferroni’smultiple comparison test: wild-type littermates ver-
sus heterozygotes non-signiﬁcant (n.s.); wild-type littermates
versus homozygotes P < 0.001; heterozygotes versus homozy-
gotes P < 0.05) (Fig. 5). Western blot analyses in KI140CAG mice
showed reduced expression of Crym protein in the striatum
Figure 1. Western blot analysis of the expression of Crym protein in the
mammalian brain. Representative western blots of total protein extracts
prepared from adult mouse (Ms) and rat striatum (St) and cerebral cortex (Cx)
(parietal) (A) and from macaque caudate (Cd), putamen (Put) and cerebral
cortex (motor cortex) (B). (C) Semi-quantitative analysis of western blots of
macaque brain extracts indicating preferential expression of Crym in caudate
and putamen when compared with cerebral cortex. *P < 0.006; one-way ANOVA
(P < 0.01) and post hoc Bonferroni test.
Figure 2. Cytosolic localization of Crym in neurons. Western blot analysis of the cytosolic (cyt) and membrane (mb) fractions after differential centrifugation of
homogenates prepared from the rat striatum and cerebral cortex (parietal). (A) Representative western blot. (B) Quantitative analysis of western blots. Results are
expressed as mean ± S.E.M. #P < 0.004 ; *P < 0.003; one-way ANOVA (P < 0.001) and post hoc Bonferroni test.
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when compared with age-matched wild-type littermates in
homozygous mice with a trend to decrease in heterozygous
mice (mean protein expression normalized with tubulin ± S.E.
M., wild-type littermates (n = 3), 4.15 ± 0.34; heterozygotes (n = 8),
3.21 ± 0.32 n.s.; homozygotes (n = 8), 2.27 ± 0.13 ; P < 0.01. One-way
ANOVA: P < 0.01, F = 11.13; post hoc Bonferroni’smultiple compari-
son test: wild-type littermates versus heterozygotes n.s.; wild-
type littermates versus homozygotes P < 0.01; heterozygotes ver-
sus homozygotes n.s.). Expression levels in the cortex were very
low and could not be reliably quantiﬁed (not shown). Thus, these
results show that Crym expression is down regulated in HDmod-
els at both the mRNA and protein levels.
Crym overexpression reduces the toxicity
of an N-terminal fragment of mHtt
We next examined whether overexpressing Crym could modify
the toxicity of an N-terminal fragment of mHtt. We ﬁrst designed
and characterized an LV to increase Crym expression in vivo (LV-
Crym-HA). For the quantitative analysis of Crym-HA mRNA
expression when compared with endogenous Crym, LV-Crym-
HA was mixed with an LV expressing GFP (LV-GFP) to allow dis-
section of the infected region under ﬂuorescence binoculars.
A lentivirus encoding β-galactosidase (LV-LacZ) was used as a
control of viral load. The ﬂuorescent region expressing GFP (and
thus Crym-HA) was dissected out for mRNA expression analysis.
Results of the quantitative RT-PCR (qRT-PCR) showed that
LV-Crym-HA produced a 14.6-fold increase of Crym expression
compared with control (LV-LacZ) [mean mRNA expression ±S.E.M.;
LacZ (n = 4), 0.030 ± 0.005; Crym-HA (n = 4), 0.437 ± 0.049; P < 0.0002,
unpaired Student’s t-test] (Supplementary Material, Fig. S1). Thus,
the LV-Crym-HA was efﬁcacious to increase Crym expression in
the mouse striatum.
To study the effect of Crym overexpression on the neurotox-
icity of mHtt in striatal neurons in vivo, we used a lentiviral
model of HD in which stereotaxic injection of an LV encoding a
short fragment of mHtt (LV-Htt171-82Q) produces a progressive
loco-regional cell dysfunction and degeneration characterized
by mHtt- and ubiquitin-containing inclusions, loss of markers
linked to neuronal integrity and astrogliosis within 6 weeks
Figure 3. Recombinant Crym in cultured cells. HEK293T cells were transfected with a Crym-HA vector (A, B). Neurons were transfected with eGFP-Crym construct. (A)
Western blot showing the detection of recombinant Crym-HA protein as a single band using either an anti-HA or an anti-Crym antibody. (B) Immunoﬂuorescence
detection of Crym-HA in HEK293T cells. (C) Expression of the eGFP-Crym protein in striatal neurons in primary culture. Images were obtained using confocal
microscopy. Scale bars: 5 and 1 μm in left and right image, respectively; 10 μm in (C).
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(33,36–38). This versatile model is particularly suitable to assess
in vivo how mHtt toxicity can be modiﬁed by different factors
that can be co-expressed with themutant protein using injection
of a mixture of LVs in mouse striatum (for a review 33).
We stereotaxically injected amixed suspension of LV-Htt171-
82Q and LV-Crym-HA into the mouse striatum. At 6 weeks post-
infection, LV-Htt171-82Q produced a loss of NeuN and DARPP32
labeling in vicinity of the injection site, indicating overt neurode-
generation (Fig. 6). In separate experiments, we checked that co-
infection with LV-LacZ (control) did not change the size of the
lesion seen using NeuN immunohistochemistry when compared
with LV-Htt171-82Q alone [data not shown; mean ± S.E.M.; NeuN,
LV-Htt171-82Q alone (n = 8), 0.440 ± 0.043 m3; LV-Htt171-82Q+
LV-LacZ (n = 6), 0.526 ± 0.088 m3; unpaired Student’s t-test,
n.s.]. Quantitative histological evaluation using NeuN immuno-
histochemistry showed that the striatal lesions produced by a
mixture of LV-Htt171-82Q and LV-Crym-HA were signiﬁcantly
smaller than those produced by LV-Htt171-82Q mixed with
LV-LacZ (Fig. 6) [mean NeuN-depleted volume ± S.E.M.; LV-
Htt171-82Q+LV-Crym-HA (n = 10), 0.229 ± 0.033 m3; LV-Htt171-
82Q+LV-LacZ (n = 7), 0.442 ± 0.095 m3; Student’s t-test, P < 0.03].
In line with this, analysis of striatal degeneration using COX
histochemistry also showed that the overexpression of Crym re-
duced the lesions produced by LV-Htt171-82Q (Fig. 6) [mean COX-
depleted volume ± S.E.M.; LV-Htt171-82Q+LV-Crym-HA (n = 10),
0.236 ± 0.024 m3; LV-Htt171-82Q+LacZ (n = 7), 0.360 ± 0.057 m3;
unpaired Student’s t-test, P < 0.05]. In contrast, analysis of striatal
degeneration using DARPP-32 immunohistochemistry did not
show signiﬁcant differences between groups (Fig. 6) [mean
DARPP-32-depleted volume ± S.E.M.; LV-Htt171-82Q+LV-Crym-
HA (n = 10), 0.450 ± 0.043 m3; LV-Htt171-82Q + LV-LacZ (n = 7),
0.444 ± 0.023 m3; unpaired Student’s t-test, n.s.].
We also assessed the number and size of Em48-positive nu-
clear inclusions in mice (Fig. 6) injected with a mixture of LV-
Htt171-82Q and LV-Crym-HA or a mixture of LV-Htt171-82Q and
LV-LacZ. Microscopic quantitative analysis of the sections pro-
cessed by Em48 antibody-immunohistochemistry showed that
overexpression of Crym has a tendency to increase the number
of Em48-containing inclusions [mean inclusion number ± S.E.M.;
LV-Htt171-82Q+LV-Crym-HA (n = 8), 36 306 ± 4091; LV-Htt171-82Q+
LV-LacZ (n = 6), 29 525 ± 7112; Student’s t-test, n.s.]. The mean size
of Em48-positive inclusions did not show differences bet-
ween groups [inclusion size, LV-Htt171-82Q+ LV-Crym-HA (n = 8),
19.09 ± 1.48 μm2; LV-Htt171-82Q+LV-LacZ (n = 6), 18.39 ± 1.86 μm2;
unpairedStudent’s t-test, n.s.]. Themeandensityof Em48-positive
inclusions permillimeter squared shows a higher tendency in the
LV-Crym-HA injected mice [density inclusions/mm², LV-Htt171-
82Q+ LV-Crym-HA (n = 8), 935.42 ± 62.48 μm2; LV-Htt171-82Q+LV-
LacZ (n = 6), 831.63 ± 48.15 μm2; unpaired Student’s t-test, n.s.].
The number and size of ubiquitin-positive nuclear inclusions
were not different from what was observed with Em48 staining
(data not shown).
Figure 4. Recombinant Crym-HA expression in neurons after lentiviral infection of the mouse striatum. Photomicrographs showing the expression of Crym-HA 6 weeks
after intrastriatal injection of LV-Crym-HA as revealed using anti-HA immunohistochemistry. (A) Low power magniﬁcation showing the expression in the anterior
striatum. (B) Higher magniﬁcation showing densely labeled/compact neurons expressing Crym-HA. (C–E) Typical isolated striatal neurons expressing Crym-HA at
distance from the core of the infection showing typical medium-size spiny neurons morphology. Note in (D) and (E) the dense labeling in the entire soma, and the
presence of immunopositive dendritic spines (white arrowheads). Scale bars: 200 μm in (A), 20 μm in (B) and (C), 10 μm in (D) and (E).
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Discussion
The mechanisms underlying the vulnerability of the striatum in
HD remain unclear. In the present study, we tested the hypoth-
esis that the protein Crym may play a role in the susceptibility
of adult striatal neurons to mHtt.
Our results show that expression of CrymmRNA is reduced in
KI140mice and BACHDmice. This is in agreement with the down
regulation of its mRNAwe and others previously found in differ-
ent HD mouse models and HD patients (11,31,32,39). In addition,
we also show that the levels of the protein Crym is markedly re-
duced in KI140 mice, indicating that down regulation that occurs
at themRNA levels leads to loss of the protein, likely impairing its
function in the striatum. We reasoned that this reduction in
Crym expression could participate in the striatal vulnerability
tomHtt toxicity. Results of our study indicated that Crym overex-
pression could reduce the susceptibility of striatal neurons in vivo
toward the toxicity of an N-terminal fragment of human mHtt.
The effect of the continuous expression of mHtt in lentiviral
models has been characterized by the loss of expression of
three markers, DARPP-32, NeuN and COX (33). The loss of NeuN
immunoreactivity and the loss of COX histochemical labeling
Figure 5. Crym expression in the KI140CAG mouse model of HD. Endogenous
Crym expression was characterized by qRT-PCR (A) in the striatum and by
western blot (B–D) in the striatum and cerebral cortex of knock in heterozygous
(+/KI) and homozygous (KI/KI) 140CAG mice and wild-type littermates (+/+).
Results are expressed as mean ± S.E.M. (n = 3–8). *P < 0.05; **P < 0.01; one-way
ANOVA and post hoc Bonferroni test.
Figure 6. Effects of Crym-HA overexpresson in the striatum on the neurotoxicity
of an N-terminal fragment of mHtt. Adult male mice received a bilateral
intrastriatal injection of LV-Htt171-82Q mixed with either LV-LacZ (control) or
an LV coding for Crym-HA (LV-Crym-HA). Six weeks after infection, brains
were processed for histological evaluation using NeuN, DARPP-32 and
Cytochrome oxidase (COX) histochemistry to assess the mHtt171-82Q toxicity.
Left panel: typical coronal mouse brain sections where areas with depleted
staining are delineated. Right panel: histograms representing quantitative
determination of the volume of the striatum with depleted staining in the
different groups and the number of ubiquitin-positive inclusions. Results are
expressed as mean (n = 7–10/group) ± S.E.M. Scale bars: Neun, Cox, DARPP32,
100 μm; EM48 upper images, 200 μm; EM48 lower images, 20 μm. *P < 0.05;
unpaired Student’s t-test.
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are associated with actual neuronal degeneration and dysfunc-
tion, as assessed usingmarkers of cell death (40) and stereological
cell counts (34). Thus, the present results indicate that overexpres-
sing Crym reduces cell death induced by the mHtt fragment.
The number and size of Em48- and ubiquitin-positive inclu-
sions in the striatum, a neuropathological hallmark of HD, were
not signiﬁcantly changed by the overexpression of Crym. This
suggests that the neuroprotective effects produced by the in-
creased expression of Crym in striatal neurons are likely inde-
pendent from a direct effect on mHtt expression or aggregation.
If Crym had reduced the levels of cellular mHtt, we should have
observed a lower number of inclusions. Neuroprotective effects
can be produced without major change in inclusions and aggre-
gates size or numbers. For example, expression of the Ip and Fp
subunits of mitochondrial complex II protects striatal neurons
against mHtt in vitro and in vivo, while the number and size of in-
clusions remain unchanged (36).
The neuroprotective effects of Crym overexpression using a
lentiviral approach in our mouse model are unlikely linked to
methodological bias. Indeed, we have tested different transgenes
using the very same methods. Recently, we studied the striatal
marker Capucin (Syndig1l) whose expression is markedly re-
duced in HD patients and mouse models (38). Overexpression of
Capucin, using a similar LV-mediated approach produced no sig-
niﬁcant change in the toxicity of LV-Htt171-82Q in the striatum.
Using similar co-infection approaches in rats, we have also iden-
tiﬁed the neuroprotective roles of some proteins against mHtt
fragment, including the transcription factor CA150 (41), chaper-
one proteins (42), signaling proteins of the JNK pathway (43),
the MSK-1 (30) and the subunits of mitochondrial complex II (36).
The mechanisms underlying reduced expression of Crym
mRNA (and, as shownhere, of Crymprotein aswell) are unknown.
The down regulation of striatal transcripts in HD may result from
the functional disruption of striatum-speciﬁc transcriptional ac-
tivators such as Bcl11b (44). Depending on the transcript, this
phenomenon can be protective, detrimental or have no effect
on striatal neurons (20). The down regulated expression of sev-
eral proteins enriched in the striatum and involved in different
neuronal functions such as neurotransmission, intracellular
signaling and transcription have been reported to play a role in
striatal vulnerability in HD. For example, compelling experimen-
tal evidence shows that the loss of A2A-R, CB1-R, MSK-1, STEP61,
Bcl11b and Fox1b likely renders striatal cells more prone to
degeneration in HD models (for a review 20,45,).
The mechanisms of whereby Crym may reduce the vul-
nerability of striatal neurons tomHtt are not yet elucidated. How-
ever, this may have to be associated with the possible alteration
in the levels of the THs in HD patients, given that THs regulate
multiple cellular events, including energy expenditure and cellu-
lar differentiation (46). In their pioneering studies, Aziz and colla-
borators showed that levels of T3, which is a ligand of Crym, are
increased in a small cohort of HD patients when compared with
age-matched controls (47). In a larger cohort, no signiﬁcant in-
crease in T3 was shown but the hormone levels were found to
be negatively correlated with severity of clinical impairments,
supporting the hypothesis that the thyrotropic axis is altered in
HD patients (48). In line with this, a functional interaction of
mHtt with thyroid hormone receptor (TR) and the nuclear co-
repressor NCor, which represses TR-mediated transcription,
has been reported, suggesting that mHtt may lead to abnormal
transcription of TR targets in the HD striatum (49). In the
striatum, such mechanism would be exacerbated by the loss
of Crym, which is normally expressed at high levels, likely facili-
tating the transport of T3 from the cytoplasm into the nucleus
where it interacts with TR. Further studies are awaited to
experimentally address these hypothetical T3-dependent
mechanisms.
In summary, the present results indicate that the expression
of the protein Crym in striatal neuronsmay be one of the import-
ant molecular determinants of the preferential vulnerability of
the striatum in HD and further links HD pathogenesis with pos-




Mice were housed in a temperature-controlled roommaintained
on a 12 h light–dark cycle. Food and water were available ad libi-
tum. All animal studies were conducted according to the French
regulation (EU Directive 86/609—French Act Rural Code R 214-87
to 131). The animal facilitywas approved by veterinarian inspect-
ors (authorization n°A 92-032-02) and complies with Standards
for Humane Care and Use of Laboratory Animals of the Ofﬁce of
Laboratory Animal Welfare (OLAW—n°#A5826-01). All proce-
dures received approval from the ethical committee. Adult
male C57BL/6J mice (25 g each; Charles River, Saint Germain sur
l’Arbresle, France) were used for lentiviral infections and prepar-
ation of brain extracts for biochemical studies. For biochemical
studies on endogenous Crym, brains of male Sprague-Dawleys
rats (350 g) were also used. We also had access to coronal brain
slices from a control adult macaque fascicularis.
For the study of endogenous CrymmRNA levels in the context
of HD, we used the transgenic mouse model of HD generated and
maintained in the FvB inbred background, the BACHD mice, that
express full-length humanmHtt from its own regulatory elements
on a 240 kb BAC,which contains the intact 170 kb human htt locus
plus ∼20 kb of 5′ ﬂanking genomic sequence and 50 kb of 3′ (50).
We used 6-month-old male BACHD mice for the present study, a
time point where there is no detectable striatal atrophy (51).
We also studied 13-month-old knock-in mice expressing chi-
mericmouse/human exon 1 containing 140 CAG repeats inserted
in themurineHtt gene (KI140) and their littermate controls. KI140
colony was maintained by breeding heterozygotes KI140 males
and females (52). Mice were N3 (B6) on a 129 Sv × C57BL/6 J back-
ground. The resulting different genotypeswere used for the present
study. At this age, homozygous and heterozygous KI140 mice
showed no major striatal atrophy, although these animals had
motor deﬁcits (Rotarod, CAtWalk and open ﬁeld) (data not shown).
Genotyping was determined from PCR of tail snips taken at
10–15 days of age for BACHD and KI140 mice.
Lentiviral vector construction, production and infection
DNA sequences coding for GFP andmouse Crymwere cloned into
the SIN-W-PGK LV to generate LV-GFP and LV-Crym, respectively
(40). The LVs expressing an mHtt fragment (LV-Htt171 82Q) or
β-galactosidase (LV-LacZ) have been described previously
(34,37). Viral particles were produced as described elsewhere
(53). The particle content of the viral batches was determined
by ELISA for the p24 antigen (Gentaur, Paris, France). LV-Htt171-
82Qwas used at a concentration of 150 ng/μl of p24, LV-Crym and
LV-LacZ at a concentration of 100 ng/μl of p24. In experiments
performed for PCR analysis, LV-GFP was mixed with LV-Crym
or LV-LacZ at a concentration of 50 ng/μl of p24. After being an-
esthetized (ketamine/xylazine), mice received a total volume of
2 μl of lentiviral suspension into the mouse striatum as
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previously reported (37,38), using the following stereotaxic coor-
dinates: 1.0 m anterior and 2.0 m lateral to the bregma, at a
depth of 2.7 m from the dura, with the tooth bar set at 0.0 m.
Histological and cytological analyses
Animal studies
After deep anesthesia by intraperitoneal injection of a sodium
pentobarbital solution (50 μg/g of body weight), mice were trans-
cardially perfusedwith 100 ml of phosphate buffer containing 4%
paraformaldehyde at 8 ml/min. The brains were removed, post-
ﬁxed overnight in the same solution, then cryoprotected by im-
mersion in a 15% sucrose solution for 24 h followed by immersion
in a 30% sucrose solution for another 24 h. Free-ﬂoating 40 μm-
thick serial coronal sections throughout the striatum were
collected using a freezing sliding microtome (SM2400; Leica
Microsystems, Wetzlar, Germany).
Immunohistochemistry
For immunohistochemistry, sections were treated with 0.3%
hydrogen peroxide for 20 min, washed three times in phos-
phate-buffered saline (PBS), blocked in PBS containing 4.5%
normal goat serum for 1 h, then incubated 48 h at 4°C in PBS con-
taining 3% normal goat serum and one of the following anti-
bodies: rabbit anti-DARPP 32 (Santa Cruz Biotechnology, Santa
Cruz, CA, USA; 1 : 1000), mouse anti-NeuN (Millipore, Molsheim,
France; 1 : 1000), mouse anti-Em48 (Chemicon, MAB5374, Teme-
cula, CA, USA; 1 : 1000), rabbit anti-Ubiquitin (Wako Chemicals,
Neuss, Germany; 1 : 1000) or mouse anti-HA (Covance, Princeton,
NJ, USA; 1 : 1000). Sections were rinsed three times in PBS before
incubation with the appropriate anti-IgG biotinylated antibody
(Vector Laboratories, Burlingame, CA, USA) at a 1 : 1000 dilution
for 1 h. Staining was visualized by the addition of avidin-biotiny-
lated peroxidase and incubation with DAB substrate (Vector
Laboratories) for 30 s to 1 min. Stained sections were mounted
on microscopic slides.
Quantitative histological evaluation
The area of the striatal lesions resulting fromLV-Htt171-82Q infec-
tion was delineated manually by identifying the border of the le-
sion (loss of DARPP-32 and NeuN immunolabeling). Lesion area
was delineated using ×5 and ×10 objectives. Depending on the
antero-posterior extension of the lesions, 3–8 coronal sections
were analyzed for eachmouse. Observation of sections and calcu-
lation of the surface of lesioned areawere performed using a Leica
DM6000 equipped with a motorized stage and an automated
image acquisitionandanalysis system (Mercator software, Explora
Nova, La Rochelle, France). The volume of the striatal lesion (V)
was determined using the Cavalieri method (34,36,38). The num-
ber of ubiquitin-positive inclusions was quantiﬁed as previously
described (34,36,38) with the following modiﬁcations: the inter-
section distance was 320 μm (i.e. one in every seven sections
was used) and observations were performed using a ×10 objective
on an Axioplan 2 Imagingmicroscope (Carl Zeiss, Le Pecq, France)
equipped with a motorized stage and an automated image acqui-
sition and analysis system (Mercator software, Explora Nova).
With this set-up, objects with an apparent cross-sectional area
>3 μm2 (i.e. diameter ∼>1 μm) could be reliably detected.
Real-time quantitative PCR
Adultmicewere deeply anesthetized by intraperitoneal injection
of a sodium pentobarbital solution (50 μg/g of body weight)
before decapitation. The brains were immediately removed and
positioned in acoronal brainmatrix (Ted Pella, Redding, CA, USA).
For the quantiﬁcation of overexpressed Crym mRNA levels,
mice were infected with a mixture of LV-Crym-HA and LV-GFP.
Injection of LV-LacZ was used as controls for viral load. The stri-
atal region displaying ﬂuorescence was dissected out using a cir-
cular punch (1.5 m diameter) from 1 m-thick fresh coronal
brain sections visualized under a ﬂuorescence binocular (Leica).
Total RNA extraction and real-time qRT-PCR were performed as
previously described (38,54), using the following primer se-
quences for Crym mRNA Crym-U CTATGAGGGCCACAGCAACA
and Crym-L ATGACCGCCAGCAGGGAG. Primers recognized se-
quence in mouse (endogenous) Crym and recombinant Crym-HA
after viral infection.
Cell studies
The primary culture of striatal neurons has been performed as
previously described (21). These neurons were electroporated
with the mouse striatal neuron Nucleofector® kit according to
the supplier’s manual (Amaxa, Biosystem, Köln, Germany) for
detection of a chimeric eGFP-Crym construct.
Human embryonic kidney 293T (HEK293T) cells were grown at
37°C in 5% CO2 in Dulbeco’s modiﬁed Eagle’s medium supple-
mentedwith 10% bovine calf serum, 1% -glutamine and antibio-
tics (50 units/ml penicillin and 50 μg/ml streptomycin). For the
study of recombinant Crym, cultured cells were seeded on glass
coverslips, and transfected with recombinant Crym-HA vector
or equivalent amount of empty vector for HEK293T cells, and
48 h later ﬁxed with cold-ice methanol and EGTA. Cells were
rinsed with TBST, and blocked with 2% bovine serum albumin
(BSA), 0.1% Tween-20 in TBS. Primary polyclonal antibody rabbit
anti-HA (H6908, Sigma, St Louis, MO, USA; 1 : 800) was used at
2 μg/ml in 2% BSA, 0.1% Triton X-100, 0.1% azide in PBS and incu-
bated for 1 h at room temperature. Similar attempt to detect na-
tive recombinant Crym protein using the afﬁnity puriﬁed IgY
chicken anti-Crym (Michel—see below for western blot) were
also used unsuccessfully. Cells were washed with 0.05% Tween-
20 in PBS and incubatedwith the appropriate ﬂuorescent second-
ary antibody for 1 h. Nuclei were counterstained with Hoechst
(DAPI). Coverslips were mounted in FluorSafe and examined
with a Leika microscope ﬁtted with the appropriate ﬂuorescence
ﬁlters, Retiga camera and Morphostrider imaging software prior
to analysis in Confocal Zeiss LSM for eGFP-Crym in primary cul-
tures and the SPE TCS Leica confocal with Leica LAS AF interface
for the HEK experiments.
Biochemical analysis
Cell preparation
Cellswere harvested 48 h after transfection and lyzed inmodiﬁed
RIPA buffer: 50 mTris, pH 8.0, 50 mNaCl, 1 m EDTA, 0.5%Tri-
ton X-100, 1% NP40 and protease inhibitor cocktail (Roche). Cell
lysates were centrifuged at 15 000 g for 20 min at 4°C.
Brain tissue preparation
Mice and rats were euthanized by rapid decapitation and brains
were removed, blocked and cut into 1 mm-thick coronal slices
using brainmatrices (Ted Pella, Redding, CA, USA). On one coronal
slice (+1 m from bregma), tissue punches were taken from the
striatumusing a tissue corer (1.5 mm indiameter) and the cerebral
cortex was dissected out using scalpel blades under binoculars.
Cortical and striatal (caudate and putamen) tissue samples
were prepared from a control non-human primate (macaca
1570 | Human Molecular Genetics, 2015, Vol. 24, No. 6
fascicularis, #2055, male ∼7 years old). Brieﬂy, the animal re-
ceived a lethal dose of pentobarbital, brain was rapidly removed
from the skull and cut into 5 m-thick coronal slabs. Slabs were
put on ice-cooled Petri dish and the pre-commissural putamen,
caudate and a piece of cerebral cortex (gray matter ribbon) in
the somato-sensori cortex were dissected out using a scalpel
blade.
For determination of total level of Crym expression in brain
tissue, punches were lysed in 50 m Tris, pH 8, 150 m NaCl,
1 m EDTA, 0.5% Triton X-100 and 1%NP40, with protease inhibi-
tor cocktail (Complete, Roche) and phosphatase inhibitor cocktail
2 (Sigma) using glass–glass pestle potters.
Differential centrifugation experiments were performed to
determine the cytosolic levels of Crym in comparison with cell
membranes, tissue punches were homogenized in solution A
containing 50 m Tris, pH 7.4, 100 m NaCl, 0.25  sucrose
with protease inhibitor cocktail (Complete, Roche) using a Teﬂon
pestle and Thomas potter. After 10 min centrifugation at 10 000 g,
the supernatant S2 was collected and centrifuged at 135 000 g,
30 min 4°C. The corresponding supernatant (S0) contained the
cytosolic fraction, whichwasmixed in Laemli. The pellet P2 (con-
taining membranes) was re-suspended to further remove cyto-
solic contaminants, placed on a 1.7  sucrose cushion and
centrifuged at 135 000 g for 30 min at 4°C. The material (mem-
branes) blocked at the 0.25/1.7  sucrose interface was collected
and re-suspended in solution A, then centrifuged again 30 min
at 135 000 g, 4°C to remove sucrose; pellet was re-suspended in
Laemli before electrophoresis.
Western blotting
Total protein concentrations were determined using the BCA kit
(Pierce). Equal amounts of total protein extract were subjected to
SDS–PAGE in 4–12% Bis–Tris gels (NuPAGE® Novex Bis-tris midi
gel 15 wells, Invitrogen) and transferred to nitrocellulose mem-
branes. Blocked membranes (5% milk in TBS–0.1% Tween-20)
were incubated with primary antibodies: Crym [1 : 500, chicken
IgY directed against AVGASRPDWRELDDE and afﬁnity puriﬁed
(AgroBio)], actin (1 : 2000, mouse, Sigma), HA (1 : 3000, mouse,
Covance), Dopamine- and cAMP-regulated PhosphoProtein 32
kDa (DARPP-32, 1 : 3000, rabbit, Cell Signaling), α-tubulin (1 : 3000,
mouse, Sigma); andwashed three timeswith TBS–0.1%Tween-20
(TBST) for 10 min. Membranes were then labeled with secondary
IgG-HRP antibodies raised against each corresponding primary
antibody. After threewasheswith TBST, themembraneswere in-
cubated with ECL chimioluminescent reagent (Clarity Western
ECL substrate; Bio-Rad or Immun-Star WesternC kit) according
to the instructions of the supplier. Peroxydase activity was de-
tected with camera system Fusion TX7 (Fisher Scientiﬁc). Nor-
malization was done by densitometry analysis with Bio1D
software.
Supplementary Material
Supplementary Material is available at HMG online.
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